Close Menu

lymphoma

The Swiss-American bioinformatics company touts its networks of multimodal data and numerous partnerships as it looks to support "data-driven medicine."

In PLOS this week: computational tool to uncover selection within populations, sequencing-based analysis of canine lymphoma, and more.

In PNAS this week: epigenetic study of Kaposi's sarcoma-associated herpesvirus, non-coding variant prioritization tool, and more.

Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.

The company will provide proprietary algorithms for analyzing omics and imaging data to define predictors of drug response and identify new biomarkers.

Transcriptomic and multi-omic data spanning more than 10,000 samples helped map "immunogenomic" interactions that may inform treatment outcomes and targets.

Investigators are planning to further validate specific applications, such as prediction of lung and lymphoma cancer subtypes, in independent sample sets.

The accelerated approval is based on results from two cohorts of a Phase II, single-arm trial in which EZH2-mutated patients had an overall response rate of 69 percent.

A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.

Pages

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.